Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction?

Blood

Volumn 97, Issue 5, 2001, Pages 1180-1195

  Vamvakas, Eleftherios C ^a   Blajchman, Morris A ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD TRANSFUSION; CANCER CELL; CANCER RECURRENCE; CANCER SURGERY; CHRONIC DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; GRAFT SURVIVAL; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SINGLE BLIND PROCEDURE; TUMOR GROWTH;

EID: 0035282955     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1180     Document Type: Review

References (114)

1. Effect of blood transfusions on subsequent kidney transplants
2. Blood transfusion-modulated tumor recurrence: First resuits of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery
3. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery
4. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery
5. Randomized comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery
6. Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: A randomized clinical trial
7. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery
8. Multiple blood transfusions reduce the recurrence rate of Crohn's disease
9. Post transfusion cytomegalovirus infection
10. Early transfusion and length of survival in acquired immune deficiency syndrome: Experience with a population receiving medical care at a public hospital
11. Allogeneic blood transfusions, immunomodulation and postoperative bacterial infection: Do we have the answers yet?
12. Direct transfusion effects in organ transplantation
13. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients
14. Red blood cells for cancer patients
15. Relationship between blood transfusion and tumor behavior
16. Effects of transfusion on immune function: Cancer recurrence and infection
17. Perioperative blood transfusion and cancer recurrence: Meta-analysis for explanation
18. Clinical studies of blood transfusion and cancer
19. Blood transfusions and postoperative septic complications
20. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: A meta-analysis of published randomized and nonrandomized studies
21. Blood transfusions and prognosis in colorectal cancer
22. Randomized controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer
23. Autologous blood and infections after colorectal surgery
24. Transfusion-associated cancer recurrence and infection: Meta-analysis of the randomized controlled clinical trials
25. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-analysis of unconfounded studies
26. Transfusion-associated immunomodulation and universal white cell reduction: Are we putting the cart before the horse?
27. Deleterious effects of transfusion-associated immunomodulation: Appraisal of the evidence and recommendations for prevention
28. Mechanisms of transfusion-induced immunosuppression
29. Mechanisms of transfusion-related immunosuppression
30. Immunomodulatory effects of allogeneic blood transfusions: Clinical manifestations and mechanisms
31. Peptide-mediated immunosuppression
32. Structure of HLA molecules and immunosuppressive effects of HLA derived peptides
33. Immunomodulation by soluble HLA class I
34. Induction of tolerance toward rat cardiac allografts by treatment with allochimeric class I MHC antigen and FTY720
35. Induction of tolerance by intrathymic inoculation of alloantigen
36. The role of donor class I major histocompatibility complex peptides in the induction of allograft tolerance
37. Allogeneic blood transfusion-induced enhancement of tumor growth: Two animal models showing amelioration of leukodepletion and passive transfer using spleen cells
38. Tumor growth-promoting effect of allogeneic blood transfusion
39. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of timing of the leukodepletion
40. Induction of humoral immune tolerance to major histocompatibility complex antigens by transfusions of UV-B irradiated leukocytes
41. Cytokine secretion after allogeneic or autologous blood transfusion
42. The effects of blood transfusion on cytokine production by Th1 and Th2 lymphocytes in the mouse
43. Blood transfusion and immunomodulation: A possible mechanism
44. Unusual kinetics of white cell clearance in transfused mice
45. Biologic effects of leukocytes present in transfused cellular blood products
46. Blood transfusion and tumor growth in animal models
47. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients
48. Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion
49. Can Creutzfeldt-Jakob disease be transmitted by transfusion?
50. New variant Creutzfeldt-Jakob disease (nvCJD): The risk of transmission by blood transfusion and the potential benefit of leukocyte-reduction of blood components
51. Leukocyte reduction of blood components: Public policy and new technology
52. A multicenter randomized controlled trial of transfusion requirements in critical care
53. Universal WBC reduction
54. Rationale, objectives, and interpretation of the findings of clinical studies of the immunomodulatory effects of blood transfusion
55. Meta-analysis in clinical research
56. Meta-analysis in clinical trials
57. Platelet production in the Old World - And the New
58. Time-dependent, spontaneous release of white cell- and platelet-derived bioactive substances from stored human blood
59. Detrimental effects of perioperative blood transfusion
60. Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: Effect of the length of storage of transfused red cells
61. Blood transfusion and infection after colorectal cancer surgery
62. Perioperative blood transfusion and outcome after resection for colorectal carcinoma
63. Publication bias in clinical research
64. Publication bias and dissemination of clinical research
65. Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards
66. Prostate cancer recurrence in radical surgery patients receiving autologous or homologous blood
67. Specific HLA class I downregulation is an early event in cervical dysplasia associated with clinical progression
68. Blood transfusion and postoperative infection in orthopedic patients
69. Adverse effects of perioperative blood transfusion in patients with colorectal cancer
70. Blood transfusion and septic complications after hip replacement surgery
71. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair
72. Blood transfusions and postoperative wound infection
73. Transfusion of white cell-containing allogeneic blood components and postoperative wound infections: Effect of confounding factors
74. Allogeneic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection
75. Relationship of postoperative septic complications and blood transfusions in patients with Crohn's disease
76. Risk of postoperative septic complications after abdominal surgical treatment in relation to perioperative blood transfusion
77. Relationship of transfusion and infectious complications after gastric carcinoma operations
78. Transfusion of buffy-coat-depleted blood components and risk of postoperative infection in orthopedic patients
79. Comparison of one dose versus three doses of prophylactic antibiotics, and the influence of blood transfusion, on infectious complications in acute and elective colorectal surgery
80. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions
81. Clinical benefits of autologous blood transfusion: An objective assessment
82. Postoperative infections following autologous and homologous blood transfusion
83. Reduction of postoperative infection by the use of autologous reinfusion
84. A clinical and immunologic study of blood transfusion and postoperative bacterial infection in spinal surgery
85. Loss of HLA-A, B, C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia
86. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma
87. The occurrence of malignant tumors in immunosuppressed states
88. Blood transfusions and local tumor recurrence in colorectal cancer: Evidence of a noncausal relationship
89. A comparison of two methods of estimating a common risk difference in a stratified analysis of a multicenter clinical trial
90. Comparison of multicenter study designs for investigation of carotid endarterectomy efficacy
91. Multicenter clinical trials: Bradford Hill's contributions and some subsequent developments
92. Multicenter randomized controlled trials in transfusion medicine
93. Method for separating patient and procedural factors while analyzing interdepartmental differences in rates of surgical infections: The Israeli study of surgical infection in abdominal operations
94. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
95. Subverting randomization in controlled trials
96. A proposal for an individual patient data based meta-analysis of randomized controlled trials of allogeneic transfusion and postoperative bacterial infection
97. Meta-analysis of the literature or individual patient data: Is there a difference?
98. CDC definitions for nosocomial infections, 1988
99. Mortality after allogeneic blood transfusion
100. Clinical significance of leukoreduction of blood components
101. Modifying risk for extracorporeal circulation: Trial of four anti-inflammatory strategies
102. Determinants of prolonged mechanical ventilation after coronary artery bypass grafting
103. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery
104. Analysis of variables affecting wound healing after musculoskeletal sarcoma resections
105. Factors related to multiple organ system failure and mortality in a surgical intensive care unit
106. Role of blood transfusion in organ system failure following major abdominal surgery
107. Oxygen delivery is an important predictor of outcome in patients with ruptured aortic aneurysms
108. Transfusions in critically ill patients
109. Evidence-based medicine: A new approach to teaching the practice of medicine
110. How blind is doubleblind? And does it matter?
111. Cost-effectiveness of expanded human immunodeficiency virus testing protocols for donated blood
112. The cost-effectiveness of preoperative autologous blood donations
113. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion